Connection

M ATASSI to Humans

This is a "connection" page, showing publications M ATASSI has written about Humans.
Connection Strength

0.536
  1. A proof-of-principle bite force study using two experimental test denture adhesives and a currently marketed denture adhesive. Clin Exp Dent Res. 2020 04; 6(2):266-273.
    View in: PubMed
    Score: 0.017
  2. Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis. Appl Microbiol Biotechnol. 2017 Nov; 101(22):8165-8179.
    View in: PubMed
    Score: 0.015
  3. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.015
  4. Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017 10; 190:257-264.
    View in: PubMed
    Score: 0.015
  5. Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. J Neuroimmunol. 2017 05 15; 306:31-39.
    View in: PubMed
    Score: 0.014
  6. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.014
  7. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.013
  8. Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions. Toxicon. 2015 Dec 01; 107(Pt A):50-8.
    View in: PubMed
    Score: 0.013
  9. MHC Genes Linked to Autoimmune Disease. Crit Rev Immunol. 2015; 35(3):203-51.
    View in: PubMed
    Score: 0.012
  10. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other. Protein J. 2014 Jun; 33(3):278-88.
    View in: PubMed
    Score: 0.012
  11. Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates. J Neuroimmunol. 2014 Jul 15; 272(1-2):29-34.
    View in: PubMed
    Score: 0.012
  12. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.010
  13. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients. Autoimmunity. 2012 Mar; 45(2):153-60.
    View in: PubMed
    Score: 0.010
  14. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.010
  15. Does Clostridium botulinum neurotoxin A exhibit molecular mimicry with thyroid autoantigens and cause thyroid complications in predisposed persons? Endocrine. 2011 Aug; 40(1):140-1; author reply 142-3.
    View in: PubMed
    Score: 0.010
  16. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.010
  17. Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates. Immunol Lett. 2011 Jun 30; 137(1-2):46-52.
    View in: PubMed
    Score: 0.009
  18. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
    View in: PubMed
    Score: 0.009
  19. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States. Int J Immunogenet. 2011 Feb; 38(1):55-62.
    View in: PubMed
    Score: 0.009
  20. Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011 May; 44(3):167-76.
    View in: PubMed
    Score: 0.009
  21. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol. 2010; 30(2):167-87.
    View in: PubMed
    Score: 0.009
  22. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon. 2009 Oct; 54(5):600-13.
    View in: PubMed
    Score: 0.008
  23. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.008
  24. The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies. Biochem Biophys Res Commun. 2008 Nov 21; 376(3):631-2.
    View in: PubMed
    Score: 0.008
  25. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.008
  26. Molecular mechanisms of autoimmunity. Autoimmunity. 2008 Mar; 41(2):123-32.
    View in: PubMed
    Score: 0.008
  27. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol. 2008 Feb; 45(4):910-24.
    View in: PubMed
    Score: 0.007
  28. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
    View in: PubMed
    Score: 0.007
  29. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action. Crit Rev Immunol. 2007; 27(4):319-41.
    View in: PubMed
    Score: 0.007
  30. Preface: Immunology of protein and peptide therapies. Crit Rev Immunol. 2007; 27(3):vii-viii.
    View in: PubMed
    Score: 0.007
  31. Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease. Crit Rev Immunol. 2007; 27(3):271-88.
    View in: PubMed
    Score: 0.007
  32. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.007
  33. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology (Reading). 2006 Jul; 152(Pt 7):1891-1895.
    View in: PubMed
    Score: 0.007
  34. Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity. 2006 Jun; 39(4):277-88.
    View in: PubMed
    Score: 0.007
  35. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
    View in: PubMed
    Score: 0.007
  36. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods. 2006 Mar 15; 151(2):90-6.
    View in: PubMed
    Score: 0.007
  37. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol. 2006 Feb; 171(1-2):8-16.
    View in: PubMed
    Score: 0.007
  38. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity. 2005 Mar; 38(2):161-9.
    View in: PubMed
    Score: 0.006
  39. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor alpha-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol. 2005 Jan; 66(1):32-42.
    View in: PubMed
    Score: 0.006
  40. Oxygen-binding heme complexes of peptides designed to mimic the heme environment of myoglobin and hemoglobin. Protein J. 2005 Jan; 24(1):37-49.
    View in: PubMed
    Score: 0.006
  41. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004 Mar; 19 Suppl 8:S68-84.
    View in: PubMed
    Score: 0.006
  42. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 2004 Jan; 23(1):39-52.
    View in: PubMed
    Score: 0.006
  43. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
    View in: PubMed
    Score: 0.005
  44. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Crit Rev Immunol. 2001; 21(1-3):1-27.
    View in: PubMed
    Score: 0.005
  45. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis? Hum Immunol. 2000 Mar; 61(3):255-65.
    View in: PubMed
    Score: 0.004
  46. Subunit interacting surfaces of human hemoglobin in solution: localization of the alpha-beta subunit interacting surfaces on the alpha-chain by a comprehensive synthetic strategy. J Protein Chem. 1999 Feb; 18(2):179-85.
    View in: PubMed
    Score: 0.004
  47. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol. 1999; 19(3):219-60.
    View in: PubMed
    Score: 0.004
  48. In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies. Br J Cancer. 1998 Dec; 78(12):1578-85.
    View in: PubMed
    Score: 0.004
  49. Human glioma associated intermediate filament proteins: over-expression, co-localization and cross-reactivity. Anticancer Res. 1998 Mar-Apr; 18(2B):1333-40.
    View in: PubMed
    Score: 0.004
  50. Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro. Tumour Biol. 1998; 19(4):229-37.
    View in: PubMed
    Score: 0.004
  51. In vitro efficacy of anti-glial fibrillary acidic protein monoclonal antibodies against human malignant glioma cell lines. Jpn J Cancer Res. 1997 Nov; 88(11):1094-9.
    View in: PubMed
    Score: 0.004
  52. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. Crit Rev Immunol. 1997; 17(5-6):481-95.
    View in: PubMed
    Score: 0.004
  53. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem. 1996 Oct; 15(7):691-700.
    View in: PubMed
    Score: 0.003
  54. Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Adv Exp Med Biol. 1995; 383:141-56.
    View in: PubMed
    Score: 0.003
  55. Mapping of the polypeptide chain organization of the main extracellular domain of the alpha-subunit in membrane-bound acetylcholine receptor by antipeptide antibodies spanning the entire domain. Adv Exp Med Biol. 1994; 347:221-8.
    View in: PubMed
    Score: 0.003
  56. Molecular recognition of acetylcholine receptor. Recognition by alpha-neurotoxins and by immune and autoimmune responses and manipulation of the responses. Adv Neuroimmunol. 1994; 4(4):403-32.
    View in: PubMed
    Score: 0.003
  57. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance. Adv Exp Med Biol. 1994; 347:65-75.
    View in: PubMed
    Score: 0.003
  58. Biological activities of rat antisera raised against synthetic peptides of human thyrotropin receptor. Endocr J. 1993 Oct; 40(5):607-12.
    View in: PubMed
    Score: 0.003
  59. Amino acid substitutions outside a preselected antigenic region in hemoglobin affect the binding to monoclonal antibodies obtained by immunization with the synthetic region. J Protein Chem. 1993 Aug; 12(4):403-12.
    View in: PubMed
    Score: 0.003
  60. Autoimmune T-cell recognition sites of human thyrotropin receptor in Graves' disease. Mol Cell Endocrinol. 1993 Mar; 92(1):77-82.
    View in: PubMed
    Score: 0.003
  61. Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol Immunol. 1992 Dec; 29(12):1507-14.
    View in: PubMed
    Score: 0.003
  62. HIV envelope protein is recognized as an alloantigen by human DR-specific alloreactive T cells. Hum Immunol. 1992 May; 34(1):31-8.
    View in: PubMed
    Score: 0.003
  63. Biological activities of rabbit antibodies against synthetic human thyrotropin receptor peptides representing thyrotropin binding regions. Biochem Biophys Res Commun. 1992 Feb 14; 182(3):1369-75.
    View in: PubMed
    Score: 0.003
  64. Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):3613-7.
    View in: PubMed
    Score: 0.002
  65. The short-neurotoxin-binding regions on the alpha-chain of human and Torpedo californica acetylcholine receptors. Biochem J. 1991 Mar 15; 274 ( Pt 3):849-54.
    View in: PubMed
    Score: 0.002
  66. Autoimmune recognition profile of the alpha chain of human acetylcholine receptor in myasthenia gravis. Adv Exp Med Biol. 1991; 303:255-61.
    View in: PubMed
    Score: 0.002
  67. Paucity of humoral response in patients to glioma-associated antigen(s): antigen localization by immunofluorescence. Adv Exp Med Biol. 1991; 303:263-70.
    View in: PubMed
    Score: 0.002
  68. Preparation and characterization of antisera and of murine monoclonal antibodies to human glioma-associated antigen(s). Adv Exp Med Biol. 1991; 303:271-83.
    View in: PubMed
    Score: 0.002
  69. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the alpha-chain of human hemoglobin. J Protein Chem. 1990 Dec; 9(6):735-42.
    View in: PubMed
    Score: 0.002
  70. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the alpha subunit. Eur J Immunol. 1990 Dec; 20(12):2563-9.
    View in: PubMed
    Score: 0.002
  71. Acetylcholine receptor-alpha-bungarotoxin interactions: determination of the region-to-region contacts by peptide-peptide interactions and molecular modeling of the receptor cavity. Proc Natl Acad Sci U S A. 1990 Aug; 87(16):6156-60.
    View in: PubMed
    Score: 0.002
  72. HLA-DR peptide inhibits HIV-induced syncytia. Immunol Lett. 1990 May; 24(2):127-31.
    View in: PubMed
    Score: 0.002
  73. Mapping of the full profile of T cell allorecognition regions on HLA-DR2 beta subunit. Eur J Immunol. 1990 Apr; 20(4):713-21.
    View in: PubMed
    Score: 0.002
  74. Localization and synthesis of an insulin-binding region on human insulin receptor. J Protein Chem. 1990 Apr; 9(2):229-33.
    View in: PubMed
    Score: 0.002
  75. DR beta peptides block the antigen-specific response but not the alloresponse of a dual-reactive T-cell clone. Immunol Lett. 1990 Mar-Apr; 24(1):43-7.
    View in: PubMed
    Score: 0.002
  76. Generation of species-specific antihemoglobin antibodies by immunization with synthetic peptides of human hemoglobin. J Protein Chem. 1989 Dec; 8(6):767-78.
    View in: PubMed
    Score: 0.002
  77. Recognition sites of hemoglobin and the preparation of antibodies with preselected specificity for clinical diagnosis and forensic medicine. Nihon Hoigaku Zasshi. 1988 Dec; 42(6):469-75.
    View in: PubMed
    Score: 0.002
  78. Molecular recognition of human insulin receptor by autoantibodies in a human serum. Immunol Invest. 1988 May; 17(3):237-42.
    View in: PubMed
    Score: 0.002
  79. The regions of alpha-neurotoxin binding on the extracellular part of the alpha-subunit of human acetylcholine receptor. J Protein Chem. 1988 Apr; 7(2):173-7.
    View in: PubMed
    Score: 0.002
  80. Antigenic regions on the beta chain of human chorionic gonadotropin and development of hormone specific antibodies. Immunol Invest. 1987 Nov; 16(7):607-18.
    View in: PubMed
    Score: 0.002
  81. The continuous antigenic regions in the second domain of the beta chain of human MHC DR2 antigen: antigenic profile of the entire extracellular part of the chain. Eur J Immunol. 1987 Jun; 17(6):769-73.
    View in: PubMed
    Score: 0.002
  82. Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA-DR2 beta chain. Eur J Immunol. 1987 Apr; 17(4):497-502.
    View in: PubMed
    Score: 0.002
  83. T-cell recognition and antigen presentation of myoglobin. Adv Exp Med Biol. 1987; 225:65-87.
    View in: PubMed
    Score: 0.002
  84. Human haptoglobin binds to human myoglobin. Biochim Biophys Acta. 1986 Sep 26; 873(2):312-5.
    View in: PubMed
    Score: 0.002
  85. Antibody recognition of ragweed allergen Ra3: localization of the full profile of the continuous antigenic sites by synthetic overlapping peptides representing the entire protein chain. Eur J Immunol. 1986 Mar; 16(3):229-35.
    View in: PubMed
    Score: 0.002
  86. Antigenic structure of human haemoglobin. Localization of the antigenic sites of the beta-chain in three host species by synthetic overlapping peptides representing the entire chain. Biochem J. 1986 Mar 01; 234(2):441-7.
    View in: PubMed
    Score: 0.002
  87. Haemoglobin binding with haptoglobin. Localization of the haptoglobin-binding sites on the beta-chain of human haemoglobin by synthetic overlapping peptides encompassing the entire chain. Biochem J. 1986 Mar 01; 234(2):453-6.
    View in: PubMed
    Score: 0.002
  88. Subunit interacting surfaces of human haemoglobin. Localization of the alpha-subunit-beta-subunit interacting surfaces on the beta-chain by a comprehensive synthetic strategy. Biochem J. 1986 Mar 01; 234(2):457-61.
    View in: PubMed
    Score: 0.002
  89. Localization of the continuous allergenic sites of ragweed allergen Ra3 by a comprehensive synthetic strategy. FEBS Lett. 1985 Aug 19; 188(1):96-100.
    View in: PubMed
    Score: 0.002
  90. Discovery and implications of the immunogenicity of free small synthetic peptides: powerful tools for manipulating the immune system and for production of antibodies and T cells of preselected submolecular specificities. Crit Rev Immunol. 1985; 5(4):387-409.
    View in: PubMed
    Score: 0.002
  91. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem. 1984 Nov 15; 145(1):1-20.
    View in: PubMed
    Score: 0.002
  92. Immune recognition of serum albumin. XVI. Role of adjuvant in the autoimmune response to mouse serum albumin. Mol Immunol. 1982 Nov; 19(11):1509-12.
    View in: PubMed
    Score: 0.001
  93. Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem J. 1982 Apr 01; 203(1):201-8.
    View in: PubMed
    Score: 0.001
  94. Immune recognition of serum albumin--XIII. Autoreactivity with rabbit serum albumin of rabbit antibodies against bovine or human serum albumins and autoimmune recognition of rabbit serum albumin. Mol Immunol. 1981 Nov; 18(11):961-7.
    View in: PubMed
    Score: 0.001
  95. Haemoglobin binding with haptoglobin. Localization of the haptoglobin-binding site on the alpha-chain of human haemoglobin. Biochem J. 1981 Aug 01; 197(2):507-10.
    View in: PubMed
    Score: 0.001
  96. A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the alpha-chain of human haemoglobin. Biochem J. 1980 Oct 01; 191(1):261-4.
    View in: PubMed
    Score: 0.001
  97. Immunochemistry of serum albumin. X. Five major antigenic sites of human serum albumin are extrapolated from bovine albumin and confirmed by synthetic peptides. Mol Immunol. 1980 Jan; 17(1):139-42.
    View in: PubMed
    Score: 0.001
  98. Haemoglobin binding with haptoglobin. Unequivocal demonstration that the beta-chains of human haemoglobin bind to haptoglobin. Biochem J. 1980 Jan 01; 185(1):285-7.
    View in: PubMed
    Score: 0.001
  99. Structure and activity of ragweed antigen E. II. Allergenic crossreactivity of the subunits. J Allergy Clin Immunol. 1979 Dec; 64(6 Pt 1):539-45.
    View in: PubMed
    Score: 0.001
  100. Prediction and conformation by synthesis of two antigenic sites in human haemoglobin by extrapolation from the known antigenic structure of sperm-whale myoglobin. Biochem J. 1977 Oct 01; 167(1):275-8.
    View in: PubMed
    Score: 0.001
  101. Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle Nerve. 1993 Dec; 16(12):1293-301.
    View in: PubMed
    Score: 0.001
  102. Immunochemistry of sperm-whale myoglobin. Conformation and immunochemistry of derivatives prepared by reaction with diazonium-1H-tetrazole. Evaluation of the specificity of the reagent. Biochemistry. 1973 Feb 27; 12(5):942-7.
    View in: PubMed
    Score: 0.001
  103. Binding of thyroid hormones to human hemoglobin and localization of the binding site. J Protein Chem. 1990 Dec; 9(6):743-50.
    View in: PubMed
    Score: 0.001
  104. Specific reduction of carboxyl groups in peptides and proteins by diborane. Biochem J. 1969 Feb; 111(4):593-601.
    View in: PubMed
    Score: 0.001
  105. Significance of the amino acid composition of proteins. 1. Composition of hemoglobins and myoglobins in relation to their structure, function and evolution. J Theor Biol. 1966 Jul; 11(2):227-41.
    View in: PubMed
    Score: 0.000
  106. Infra-red spectral analysis of the apoproteins of some haemoglobins and myoglobins. Nature. 1966 Mar 19; 209(5029):1211-3.
    View in: PubMed
    Score: 0.000
  107. Immunochemical studies of hemoglobin and the role of the sulfhydryl groups. Immunochemistry. 1965 Dec; 2(4):379-89.
    View in: PubMed
    Score: 0.000
  108. Neuraminic acid and its relation to chronic bronchitis. V. Glass column electrophoresis of sputum. Clin Chim Acta. 1962 Sep; 7:706-9.
    View in: PubMed
    Score: 0.000
  109. Genetic control of the immune response to haemoglobin. IV. Ly-1+ T-cells and appropriate non-H-2 genes are required for in vitro responses to alpha- and beta-subunits of human adult haemoglobin. J Immunogenet. 1982 Apr; 9(2):93-100.
    View in: PubMed
    Score: 0.000
  110. Genetic control of the immune response to hemoglobin and its subunits. Adv Exp Med Biol. 1982; 150:127-40.
    View in: PubMed
    Score: 0.000
  111. Genetic control of the immune response to haemoglobin. III. Variant A beta (bm12) but not Ae (D2.GD) Ia polypeptides alter immune responsiveness towards the alpha -subunit of human haemoglobin. J Immunogenet. 1981 Dec; 8(6):471-6.
    View in: PubMed
    Score: 0.000
  112. Genetic control of the immune response to haemoglobin. II. Studies using purified alpha-chain and beta-chain as immunogens. J Immunogenet. 1981 Oct; 8(5):395-403.
    View in: PubMed
    Score: 0.000
  113. Neuraminic acid and its relation to chronic bronchitis. III. Carbohydrate constituents of sputum. Clin Chim Acta. 1959 Nov; 4:823-7.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.